Newsfeeds Archive - Page 17 of 56

2 minute read

Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At ‘Psychedelic-Assisted Therapies’

July 18, 3:54 PM

COMPASS Pathways (NASDAQ: CMPS) shared results from an open-label Phase 2 trial assessing its synthetic psilocybin COMP360 alongside SSRIs for Treatment-Resistant Depression (TRD.)

CMPS

2 minute read

Reunion Neuroscience On The Brink Of Going Private With Final Court Approval

By Lara Goldstein

July 17, 5:04 PM

Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution approving the proposed arrangement plan on July 12.

FTHWF

2 minute read

Venturing Beyond The Magic Kingdom: Former Disney CFO And Fortune 500 Veteran Takes The Reins At Lucy Scientific

By Lara Goldstein

July 14, 4:17 PM

As of July 13, Lucy Scientific Discovery (NASDAQ: LSDI) has a new principal.

AMGN

2 minute read

Psilocybin For IBS Gets FDA Nod To Begin Clinical Trials At Mass. General Hospital

By Lara Goldstein

July 13, 3:48 PM

Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at the Massachusetts General Hospital (MGH) on the effects of psilocybin-assisted psychotherapy for adults with Irritable B

TRYPF

2 minute read

Bright Minds Goes For 5:1 Shares Consolidation, Hopes To Regain NASDAQ Compliance

By Lara Goldstein

July 11, 3:25 PM

Bright Minds Biosciences Inc. (NASDAQ: DRUG) is going for a consolidation of its common shares on a five-to-one basis, a plan approved by the company’s board of directors in June.

DRUG

3 minute read

Psyched: Australia’s Innovative Program, Congressional Amendments, Therapy Reimbursement And More

By Lara Goldstein

July 11, 11:25 AM

First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic stress disorder (PTSD) and psilocybin to combat treatment-resistant depression.

AWKNF

2 minute read

H&W News: Panacea Life Sciences Diversifies, Deepak Chopra’s Healing Company Uplists To OTCQB

By Lara Goldstein

July 8, 3:14 PM

Colorado-based Panacea Life Sciences Holdings (OTCQB: PLSH) is expanding its natural Health and Wellness (H&W) division through a spectrum of products based on kratom and kava as well as the potential acquisition of plant-based non-alcoholic health and energy drinks and vaping products. </

HLCO

2 minute read

Filament Supplies Botanical Psilocybin To Canadian Researchers, Inks Global Licensing Deal

By Lara Goldstein

July 7, 3:51 PM

Clinical-stage natural psychedelics company Filament Health (OTCQB: FLHLF) will supply psilocybin for two clinical studies funded by the Canadian Institutes of Health Research (CIHR) operating grants on mental health and Substance Use Disorders (SUDs.)

FLHLF

2 minute read

Can Psychedelics Therapy Be Reimbursed? AMA Releases Details On Coding These Procedures

By Lara Goldstein

July 6, 1:47 PM

The American Medical Association (AMA) published language concerning the recently-approved Current Procedural Terminology (CPT) III codes applying to psychedelic-assisted therapies, as announced by its

CMPS